Cargando…
Fabry Disease – Current Treatment and New Drug Development
Fabry disease is a rare inherited lysosomal storage disorder caused by a partial or complete deficiency of α-galactosidase A (GLA), resulting in the storage of excess cellular glycosphingolipids. Enzyme replacement therapy is available for the treatment of Fabry disease, but it is a costly, intraven...
Autores principales: | Motabar, Omid, Sidransky, Ellen, Goldin, Ehud, Zheng, Wei |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Bentham Open
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2995157/ https://www.ncbi.nlm.nih.gov/pubmed/21127742 http://dx.doi.org/10.2174/1875397301004010050 |
Ejemplares similares
-
High Throughput Screening for Inhibitors of Alpha-Galactosidase
por: Motabar, Omid, et al.
Publicado: (2010) -
High Throughput Screening for Small Molecule Therapy for Gaucher Disease Using Patient Tissue as the Source of Mutant Glucocerebrosidase
por: Goldin, Ehud, et al.
Publicado: (2012) -
Fabry Disease: The Current Treatment Landscape
por: Lenders, Malte, et al.
Publicado: (2021) -
Developments in the treatment of Fabry disease
por: van der Veen, Sanne J., et al.
Publicado: (2020) -
Current status of cardiac manifestations in Fabry disease and their treatment
por: Radulescu, Dan, et al.
Publicado: (2021)